Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...

As India steps into 2025, breakthrough weight-loss drugs, economic shifts, and global trends shape the road to a Viksit ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...